Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Non Operating Income (2020 - 2026)

Xeris Biopharma Holdings filings provide 6 years of Other Non Operating Income readings, the most recent being $18.6 million for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 374.59% to $18.6 million in Q4 2025 year-over-year; TTM through Sep 2025 was -$25.4 million, a 30.7% decrease, with the full-year FY2024 number at -$23.5 million, down 20.33% from a year prior.
  • Other Non Operating Income hit $18.6 million in Q4 2025 for Xeris Biopharma Holdings, up from -$6.1 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $18.6 million in Q4 2025 to a low of -$7.6 million in Q3 2023.
  • Median Other Non Operating Income over the past 5 years was -$4.5 million (2023), compared with a mean of -$2.8 million.
  • Biggest five-year swings in Other Non Operating Income: crashed 340.28% in 2022 and later surged 374.59% in 2025.
  • Xeris Biopharma Holdings' Other Non Operating Income stood at $5.0 million in 2021, then plummeted by 62.34% to $1.9 million in 2022, then crashed by 247.21% to -$2.8 million in 2023, then plummeted by 142.57% to -$6.8 million in 2024, then surged by 374.59% to $18.6 million in 2025.
  • The last three reported values for Other Non Operating Income were $18.6 million (Q4 2025), -$6.1 million (Q3 2025), and -$6.4 million (Q2 2025) per Business Quant data.